| Oct 8 |
TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why
|
| Sep 26 |
TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery
|
| Sep 11 |
TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment
|
| Sep 11 |
TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID
|
| Sep 10 |
TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
|
| Sep 3 |
TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 17 |
TFF Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 15 |
TFF Pharmaceuticals GAAP EPS of -$1.22 misses by $0.41, revenue of $0.65M beats by $0.5M
|
| Aug 14 |
TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 14 |
TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
|
